Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/cdd.2015.3 http://scihub22266oqcxt.onion/10.1038/cdd.2015.3 C4356349!4356349!25656654     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25656654&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Cell+Death+Differ 2015 ; 22 (4): 549-59 Nephropedia Template TP {{tp|p=25656654|t=2015. The role of CD95 and CD95 ligand in cancer |pdf=|usr=}}{{25656654}} gab.com Text The role of CD95 and CD95 ligand in cancer JO: Cell Death Differ http://www.kidney.de/pget.php?&tw=1&pmid=25656654 #FOAvip CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy. Twit Text FOAVip The role of CD95 and CD95 ligand in cancer ????Cell Death Differ http://www.kidney.de/pget.php?&tw=1&pmid=25656654 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25656654 #FOAvip English Wikipedia <ref>{{Cite pmid|25656654}}</ref> The role of CD95 and CD95 ligand in cancer #MMPMID25656654 Peter ME; Hadji A; Murmann AE; Brockway S; Putzbach W; Pattanayak A; Ceppi P Cell Death Differ 2015[Apr]; 22 (4): 549-59 PMID25656654show ga CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy. äThe role of CD95 and CD95 ligand in cancer (epmc).pdf DeepDyve Pubget Overpricing